Kit for determining bone alkaline phosphatase as well as preparation method and application thereof

By using specific antibodies and magnetic bead combinations in the bone alkaline phosphatase assay kit, the sensitivity, specificity and stability of the existing kits are solved, and efficient and convenient detection is achieved to meet clinical diagnosis and treatment monitoring. need.

CN118897079APending Publication Date: 2024-11-05SICHUAN ORIENTER BIOLOGICAL TECH
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202410989449.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-23
Publication Date
2024-11-05

AI Technical Summary

Technical Problem

The existing bone alkaline phosphatase assay kits have problems such as insufficient sensitivity, low specificity, cross-interference, complex operation, poor stability and expensiveness, which are difficult to meet the needs of clinical diagnosis and treatment monitoring.

Method used

The bone alkaline phosphatase was determined by chemiluminescence method using a combination of biotin-labeled goat anti-mouse polyclonal antibodies, murine anti-human BAP specific monoclonal antibodies and goat serum. Operation process and optimize reagent formula to improve detection sensitivity and specificity.

Benefits of technology

It significantly improves the sensitivity and specificity of bone alkaline phosphatase detection, reduces detection costs, simplifies operating procedures, improves detection efficiency, and plays an important role in bone health assessment, disease diagnosis and treatment monitoring.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118897079A_ABST
    Figure CN118897079A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of immunodetection reagents, and discloses a kit for determining bone alkaline phosphatase as well as a preparation method and application thereof, and the kit comprises a reagent R1, a reagent R2 and a reagent R3, the reagent R1 is a goat anti-mouse polyclonal antibody which is coated on streptavidin magnetic beads and is marked with biotin; the reagent R2 is a mouse anti-human BAP specific monoclonal antibody; and the reagent R3 is an analysis buffer solution added with goat serum. According to the present invention, the sensitivity, the specificity and the stability of the BAP detection can be significantly improved, the operation is simple, the detection cost of the patient can be reduced, and the significant effect can be provided in the fields of bone health evaluation, disease diagnosis, treatment effect monitoring and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of immunoassay reagents, and in particular to a kit for measuring bone alkaline phosphatase, a preparation method and an application thereof. Background Art

[0002] Bone Alkaline Phosphatase (BAP) is an important biomarker that plays a key role in bone metabolism. With the continuous development of modern biomedical technology, the research and application of BAP are becoming increasingly in-depth, and its value in clinical diagnosis and treatment monitoring is gradually highlighted. The present invention aims to provide a detection method or related application tools based on bone alkaline phosphatase to provide a more accurate and convenient means for bone health assessment, disease diagnosis and treatment effect monitoring.

[0003] Bone alkaline phosphatase is a membrane-bound glycosylation enzyme that is widely present in various tissues of the human body, especially in the skeletal system. BAP is a protease secreted by osteoblasts. It plays an important role in bone formation and mineralization. It hydrolyzes phosphate esters to provide the necessary phosphoric acid for the deposition of hydroxyapatite, and hydrolyzes pyrophosphate to relieve its inhibitory effect on bone salt formation, thereby promoting the formation of new bone.

[0004] The activity level of BAP in serum can reflect the rate of bone formation and is therefore considered an important indicator for assessing bone health. In clinical practice, BAP detection is widely used in the diagnosis and monitoring of diseases such as rickets in children, osteoporosis in postmenopausal women, and osteoarthritis deformans. In addition, since the activity of BAP is stable and not affected by day and night changes, its quantitative determination can also be used as an effective means to observe the change rate of bone formation, providing valuable reference information for clinical treatment.

[0005] At present, there are few methods and technologies for detecting BAP on the market, including immunoassay, enzyme activity assay, etc. Clinical BAP detection mainly relies on the chemiluminescence assay kit of Beckman Coulter. However, these still face some challenges in practical applications, such as insufficient sensitivity, low specificity, cross-interference, complex operation, poor stability, and high price. Therefore, the development of a BAP assay kit with high sensitivity, high specificity, low interference rate and simple operation has important practical significance and application prospects.

[0006] In view of this, this application is hereby filed. Summary of the invention

[0007] The problems existing in the prior art are that the existing BAP determination kits have the problems of insufficient sensitivity, low specificity, cross interference, complicated operation, poor stability, high price, etc. In order to solve the above problems, the present invention provides a kit for determining bone alkaline phosphatase and a preparation method and application, which can significantly improve the sensitivity, specificity and stability of BAP detection, and is simple to operate, which can reduce the detection cost of patients and can play a greater role in the fields of bone health assessment, disease diagnosis and treatment effect monitoring.

[0008] The present invention is achieved through the following technical solutions:

[0009] In a first aspect, the present invention provides a kit for determining bone alkaline phosphatase, comprising reagent R1, reagent R2, and reagent R3;

[0010] The reagent R1 is a goat anti-mouse polyclonal antibody coated on streptavidin magnetic beads and labeled with biotin;

[0011] The reagent R2 is a mouse anti-human BAP specific monoclonal antibody;

[0012] The reagent R3 is an analytical buffer added with goat serum.

[0013] In a specific embodiment, the working concentration of the goat anti-mouse polyclonal antibody in the reagent R1 is 1-4 μg / mL, and the working concentration of the magnetic beads is 0.1-0.4 mg / mL. Preferably, the working concentration of the goat anti-mouse polyclonal antibody in the reagent R1 is 2 μg / mL, and the working concentration of the magnetic beads is 0.4 mg / mL.

[0014] In a specific embodiment, the buffer of reagent R1 includes: Tris with a working concentration of 12.11 g / L, NaCl with a working concentration of 27.0 g / L, trehalose with a working concentration of 20.0 g / L, BSA with a working concentration of 10 g / L, Proclin300 with a working concentration of 1.0 mL / L, Tween 20 with a working concentration of 0.5 mL / L, and 4-aminoantipyrine with a working concentration of 0.04 g / L, added to purified water; the pH value of the buffer of reagent R1 is 7.9±0.1.

[0015] In a specific embodiment, the working concentration of the mouse anti-human BAP specific monoclonal antibody in the reagent R2 is 0.01-0.1 μg / mL. Preferably, the working concentration of the mouse anti-human BAP specific monoclonal antibody in the reagent R2 is 0.05 μg / mL.

[0016] In a specific embodiment, the buffer of reagent R2 includes: Tris with a working concentration of 12.11 g / L, NaCl with a working concentration of 18.0 g / L, trehalose with a working concentration of 10.0 g / L, BSA with a working concentration of 10 g / L, Proclin300 with a working concentration of 1.0 mL / L, Tween 20 with a working concentration of 0.5 mL / L, 4-aminoantipyrine with a working concentration of 0.04 g / L, fruit green pigment with a working concentration of 0.05 g / L, and Triton 100 with a working concentration of 0.5 mL / L, which are added to purified water; the pH value of the buffer of reagent R2 is 7.5±0.1.

[0017] In a specific embodiment, the concentration of goat serum in the reagent R3 is 10 mL / L.

[0018] In a specific embodiment, the reagent R3 analytical buffer comprises: goat serum with a working concentration of 10 mL / L, Tris with a working concentration of 12.11 g / L, NaCl with a working concentration of 9.0 g / L, and Proclin300 with a working concentration of 3 mL / L, added into purified water; the pH value of the reagent R3 analytical buffer is 7.1±0.1.

[0019] In a specific embodiment, the kit further comprises a calibrator and a quality control product;

[0020] The calibrator comprises BAP antigen solutions with concentrations of 0 μg / L, 4.0 μg / L, 10 μg / L, 30 μg / L, 60 μg / L, and 120 μg / L;

[0021] The quality control product comprises BAP antigen solutions with concentrations of 10 μg / mL and 60 μg / mL.

[0022] The buffer solution for calibrators and quality control products includes: Na2HPO4·12H2O with a working concentration of 2.56 g / L, NaH2PO4·2H2O with a working concentration of 0.436 g / L, NaCl with a working concentration of 9 g / L, trehalose with a working concentration of 20.0 g / L, casein with a working concentration of 20 g / L, Proclin300 with a working concentration of 3.0 mL / L, and propylene glycol with a working concentration of 10 mL / L, added into purified water; the buffer pH value of calibrators and quality control products is 7.1±0.1.

[0023] In a second aspect, the present invention also provides a method for preparing a chemiluminescent kit for determining bone alkaline phosphatase, wherein the preparation process of the reagent R1 comprises the following steps:

[0024] (1) Dilute goat anti-mouse polyclonal antibody to 1 mg / mL with 0.02 M PBS (pH 7.4), dialyze in 0.02 M PBS (pH 7.4) for 18-32 hours, and change the medium once;

[0025] (2) Biotin-labeled antibody: 2.3 mg of biotin ester was placed in a centrifuge tube and dissolved in 1 mL of dimethyl sulfoxide to prepare a biotin ester solution with a concentration of 2.3 mg / mL; the biotin ester solution was added to the dialyzed antibody at a ratio of 34.5 μg of biotin ester per 1 mg of antibody, and the reaction was allowed to proceed for 30 minutes, and then 1 M tris buffer was added to terminate the reaction;

[0026] (3) Dialyze in 0.02 M PBS (pH 7.4) for 18-32 hours, changing the medium once;

[0027] (4) recovering the antibodies after dialysis and returning them to a centrifuge tube for later use;

[0028] (5) Streptavidin magnetic beads coating: take the streptavidin-labeled magnetic beads, place them on a magnetic separator, and discard the supernatant; mix and resuspend the magnetic beads with the buffer of reagent R1, place them back on the magnetic separator, and discard the supernatant; resuspend and wash again; the washed streptavidin magnetic beads are suspended in the buffer of reagent R1;

[0029] (6) Add the biotin-labeled antibody in step (4) to the streptavidin magnetic beads in step (5) at a ratio of 0.01 mg antibody to 1 mg magnetic beads, mix well, react for 30 minutes, place on a magnetic separator, discard the supernatant, and repeat washing 3 times; suspend the magnetic beads in the buffer of reagent R1 at a volume 50 times that of the magnetic bead stock solution.

[0030] In a specific embodiment, the preparation process of the reagent R2 comprises the following steps:

[0031] (1) Antibody activation: mouse anti-human BAP-specific monoclonal antibody was first diluted to 3 mg / mL with TSE, and then dialyzed with TSE for 18-32 hours, with the solution changed once during the process;

[0032] (2) recovering antibodies, and recovering the antibodies after dialysis into a centrifuge tube for later use;

[0033] (3) Using the buffer of reagent R2, the antibody in step C is prepared to 0.2 μg / mL. At this point, the preparation of reagent R2 is complete.

[0034] In a specific embodiment, the preparation process of reagent R3 includes the following steps: taking the buffer solution of reagent R3, and adding goat serum at a working concentration of 100 mL / L.

[0035] In a third aspect, the present invention also provides an application of a chemiluminescent kit for determining bone alkaline phosphatase, which is used for detecting bone alkaline phosphatase.

[0036] The operation process and reaction principle of the bone alkaline phosphatase (BAP) chemiluminescence assay kit of the present invention are as follows:

[0037] (1) Add 20 μL of the sample to be tested, 50 μL of reagent R3 and 50 μL of reagent R2, mix well, and incubate at 37°C for 10 minutes. The mouse anti-human BAP antibody in reagent R2 reacts with the BAP molecules in the sample to be tested to form an immune complex; add 50 μL of reagent R1, mix well, and incubate at 37°C for 10 minutes. The goat anti-mouse polyclonal antibody coated on the streptavidin magnetic beads in reagent R1 reacts with the mouse anti-human BAP antibody to finally form an immune complex of solid phase-goat anti-mouse polyclonal antibody-mouse anti-human BAP antibody-BAP, place in a magnetic field, discard the supernatant, and wash three times to wash away unbound substances;

[0038] (2) Add substrate solution. BAP (bone alkaline phosphatase) can directly catalyze the substrate AMPPD to emit light, and then detect the luminescence value. The luminescence value is positively correlated with the BAP concentration.

[0039] (3) A concentration-luminescence value standard curve is drawn based on a calibrator of known concentration. The luminescence value obtained in step (2) is substituted into the drawn standard curve to obtain the concentration value of BAP in the sample to be tested.

[0040] In the above reaction principle, the cleaning solution comprises tris(hydroxymethyl)aminomethane, Tween-20, Proclin300, and sodium azide; and the substrate comprises AMPPD.

[0041] The BAP kit of the present invention has a correlation of more than 95% in sample detection with the imported kit and meets the following performance requirements:

[0042] A. Appearance: The kit components are complete, liquid reagents have no leakage, and there is no flocculent matter;

[0043] B. Blank limit: The blank limit is not higher than 0.08μg / L;

[0044] C. Linearity: In the range of 0.10μg / L to 120.00μg / L, the linear correlation coefficient r is not less than 0.9900;

[0045] D. Accuracy: relative deviation within ±10.0%;

[0046] E. Intra-assay precision: The intra-assay coefficient of variation (CV) should be no greater than 8.0%;

[0047] F. Inter-batch precision: The inter-batch coefficient of variation (CV) should not be greater than 15.0%;

[0048] G. Anti-interference: Bilirubin ≤400μmol / L, hemoglobin ≤4.0g / L, triglyceride ≤800mg / dL, biotin ≤150ng / mL in the sample will not significantly interfere with the results, and the result produced by 100U / L liver ALP is ≤4.5μg / L;

[0049] H. Stability: Accelerated stability at 37°C for 9 days is ≤10%, and long-term stability for 1-13 months is ≤10%.

[0050] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0051] 1. A kit for determining bone alkaline phosphatase, a preparation method, and an application provided in an embodiment of the present invention utilizes bone alkaline phosphatase to directly catalyze substrate luminescence, thereby eliminating the antibody labeling process in a general chemiluminescent reagent and being simple to operate;

[0052] 2. A kit for determining bone alkaline phosphatase, a preparation method, and an application provided in an embodiment of the present invention achieve a high-sensitivity and high-specificity detection effect by optimizing the reagent formula and combination mode, and the stability of the calibrator is better than that of imported reagents; at the same time, the sample requirement is small, the reaction time is short, and the detection efficiency is improved;

[0053] 3. The kit, preparation method and application for determining bone alkaline phosphatase provided in the embodiment of the present invention can significantly improve the sensitivity, specificity and stability of BAP detection, and is simple to operate, which can reduce the detection cost of patients and play a greater role in the fields of bone health assessment, disease diagnosis and treatment effect monitoring. BRIEF DESCRIPTION OF THE DRAWINGS

[0054] In order to more clearly illustrate the technical solutions of the exemplary embodiments of the present invention, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present invention and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, other related drawings can be obtained based on these drawings without paying creative work.

[0055] Figure 1 It is a standard curve diagram of the concentration-luminescence value of the BAP kit calibrator of the present invention.

[0056] Figure 2 It is a comparison chart of the measured values ​​of the BAP kit of the present invention and the imported kit samples. DETAILED DESCRIPTION

[0057] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments and drawings. The exemplary embodiments of the present invention and their description are only used to explain the present invention and are not intended to limit the present invention.

[0058] In the following description, a large number of specific details are set forth in order to provide a thorough understanding of the present invention. However, it is apparent to one of ordinary skill in the art that these specific details need not be employed to practice the present invention. In other embodiments, in order to avoid obscuring the present invention, well-known materials or methods are not specifically described.

[0059] Throughout the specification, references to "one embodiment," "an embodiment," "an example," or "an example" mean that a particular feature, structure, or characteristic described in conjunction with the embodiment or example is included in at least one embodiment of the present invention. Therefore, the phrases "one embodiment," "an embodiment," "an example," or "an example" appearing in various places throughout the specification do not necessarily all refer to the same embodiment or example. In addition, particular features, structures, or characteristics may be combined in one or more embodiments or examples in any suitable combination and / or subcombination. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0060] The "range" disclosed in this application is defined in the form of a lower limit and an upper limit. A given range is defined by selecting a lower limit and an upper limit, and the selected lower limit and upper limit define the boundaries of the particular range. The range defined in this way can be inclusive or exclusive of the end values, and can be combined arbitrarily, that is, any lower limit can be combined with any upper limit to form a range. In this application, unless otherwise specified, the numerical range "a to b" represents an abbreviation of any real number combination between a and b, where a and b are both real numbers.

[0061] Example 1

[0062] The embodiment of the present invention provides a preparation of a kit for determining bone alkaline phosphatase, the kit comprising reagent R1, reagent R2, reagent R3, a calibrator and a quality control product, and the preparation steps are as follows:

[0063] 1) Preparation of buffer solution of reagent R1:

[0064] A. Prepare clean weighing paper, place it on the balance, and adjust the zero point;

[0065] B. Weigh 12.11 g Tris and 27.0 g NaCl respectively and pour them into a 1000 mL beaker;

[0066] C. Add 800 mL of purified water to dissolve in step B and adjust the pH to between 7.9±0.1;

[0067] D. Weigh 20g trehalose, 10g BSA, and 0.04g 4-aminoantipyrine in sequence and stir until fully dissolved;

[0068] E. Use a pipette to add 1.0 mL of Proclin 300 and 0.5 mL of Tween 20 to the solution in step D;

[0069] F. Use purified water to make the solution volume up to 1.0 L and prepare the buffer solution of reagent R1 at pH 7.9.

[0070] 2) Preparation of reagent R1:

[0071] A. Take 2 mg of goat anti-mouse polyclonal antibody, dilute to 1 mg / mL with 0.02 M PBS (pH 7.4), and dialyze in 5 L of 0.02 M PBS (pH 7.4) for 18-32 hours, changing the solution once;

[0072] B. Weigh 1.15 mg of biotin ester into a centrifuge tube and add dimethyl sulfoxide to dissolve it to a concentration of 2.3 mg / mL;

[0073] C. Recover the goat anti-mouse polyclonal antibody prepared in step A into a suitable container, dilute it to 0.5 mg / mL with 0.02 M PBS (pH 7.4), add 40 μL of the biotin ester prepared in step B, mix well and react for 30 minutes;

[0074] D. Add 10 μL of 1M Tris to the goat anti-mouse polyclonal antibody and let stand for 10 minutes to terminate the reaction;

[0075] E. The antibody after reaction was diluted to 1 mg / mL with 0.02 M PBS (pH 7.4), and dialyzed in 5 L of 0.02 M PBS (pH 7.4) for 18-32 hours, changing the liquid once;

[0076] F. Add the antibody recovered in the previous step to 200 mg of streptavidin magnetic beads, mix well, react for 30 minutes, place on a magnetic separator, discard the supernatant, and repeat washing 3 times with the buffer of reagent R1;

[0077] Use 500 mL of reagent R1 buffer to suspend the magnetic beads. Now the preparation of reagent R1 is complete.

[0078] 3) Preparation of buffer solution of reagent R2:

[0079] A. Prepare clean weighing paper, place it on the balance, and adjust the zero point;

[0080] B. Weigh 12.11 g Tris and 18.0 g NaCl respectively and pour them into a 1000 mL beaker;

[0081] C. Add 800 mL of purified water to dissolve in step B and adjust the pH to between 7.5±0.1;

[0082] D. Weigh 10g trehalose, 10g BSA, 0.04g 4-aminoantipyrine, and 0.05g green pigment in sequence, and stir until fully dissolved;

[0083] E. Use a pipette to pipette 1.0 mL Proclin 300, 0.5 mL Tween 20, and 0.5 mL Triton 100 into the solution in step D;

[0084] F. Use purified water to make the solution volume up to 1.0 L and prepare the buffer solution of reagent R2 at pH 7.5.

[0085] 4) Preparation of reagent R2:

[0086] A. Take 0.1 mg of mouse anti-human BAP specific monoclonal antibody and dialyze it in 5 L of 0.02 M PBS (pH 7.4) for 18-32 hours, changing the liquid once;

[0087] B. Recover the antibody in step A and dilute the dialyzed mouse anti-human BAP-specific monoclonal antibody to 0.2 μg / mL using the buffer of reagent R2. At this point, the preparation of reagent R2 is complete.

[0088] 5) Preparation of reagent R3:

[0089] A. Prepare clean weighing paper, place it on the balance, and adjust the zero point;

[0090] B. Weigh 2.56 g of disodium hydrogen phosphatase dodecahydrate, 0.436 g of sodium dihydrogen phosphate dihydrate, and 9.0 g of sodium chloride respectively and pour them into a 1000 mL beaker;

[0091] C. Add 800 mL of purified water to dissolve in step B and adjust the pH to between 7.1±0.1;

[0092] D. Weigh 10g of bovine serum albumin and stir until fully dissolved;

[0093] E. Use a pipette to pipette 3.0 mL of Proclin 300 and 100 mL of goat serum into the solution in step D. The preparation of reagent R3 is now complete.

[0094] 6) Preparation of calibration and quality control buffer:

[0095] A. Prepare clean weighing paper, place it on the balance, and adjust the zero point;

[0096] B. Weigh 2.56 g of disodium hydrogen phosphatase dodecahydrate, 0.436 g of sodium dihydrogen phosphate dihydrate, and 9.0 g of sodium chloride respectively and pour them into a 1000 mL beaker;

[0097] C. Add 800 mL of purified water to dissolve in step B and adjust the pH to between 7.1±0.1;

[0098] D. Weigh 20g trehalose and 20g casein in turn and stir until fully dissolved;

[0099] E. Use a pipette to pipette 3.0 mL of Proclin 300 and 10 mL of glycerol into the solution in step D. The preparation of the calibrator and quality control buffer is now complete.

[0100] 7) Preparation of calibration products and quality control products:

[0101] A. Take one BAP antigen and prepare a certain concentration of calibration product with calibration product and quality control product buffer. The concentrations are 0.00μg / L, 4.00μg / L, 10.00μg / L, 30.00μg / L, 60.00μg / L, and 120.00μg / L respectively;

[0102] B. Take one tube of BAP antigen and prepare a quality control product with a certain concentration using the calibration product and quality control product buffer. The concentrations are 10.00μg / L and 60.00μg / L respectively.

[0103] 8) The prepared reagents R1, R2, R3, calibrators and quality control products are packaged according to the packaging requirements to obtain the BAP kit, which is stored at 2-8°C.

[0104] Example 2

[0105] The embodiment of the present invention provides a method for drawing a calibrator using the BAP kit prepared in Example 1, comprising the following steps:

[0106] A. Before using a new kit, carefully invert it several times to ensure that the magnetic beads are mixed evenly;

[0107] B. Take out the calibration sample and equilibrate it to room temperature;

[0108] C. Confirm that the fully automatic chemiluminescence immunoassay analyzer has been maintained and inspected;

[0109] D. Install the kit, operate the instrument as required, add 20 μL of calibrant, and measure the luminescence value;

[0110] E. Data processing: Table 1 shows the luminescence values ​​of the kit calibrators. Based on the calibrator concentrations and the luminescence values ​​measured, a standard curve can be obtained by four-parameter fitting, such as Figure 1 As shown, the sample concentration value can be obtained by substituting the measured sample luminescence value into the calibration curve.

[0111] Table 1: Results of luminescence values ​​(RLU) of calibration samples

[0112] Calibrators Concentration (μg / L) RLU 1 RLU 2 AVE CV S0 0.00 3198 3359 3279 3.47% S1 4.00 276557 277401 276979 0.22% S2 10.00 739569 730637 735103 0.86% S3 30.00 2209340 2167989 2188664 1.34% S4 60.00 4336743 4412346 4374545 1.22% S5 120.00 8404150 8409564 8406857 0.05%

[0113] Example 3

[0114] The present invention performs a performance evaluation on the kit prepared in Example 1:

[0115] A. Appearance

[0116] Visually inspect under natural light with normal or corrected vision to ensure that all components of the kit are complete, and that there is no leakage of liquid reagents or floccules;

[0117] B. Blank limit

[0118] The zero concentration calibrator (S0) was used as the sample for determination, and the determination was repeated 20 times to obtain the RLU values ​​of the 20 determination results, and the mean value M and standard deviation SD were calculated to obtain the RLU value corresponding to (M+2SD). Based on the concentration-luminescence value (RLU) results between the mean of the 20 tests of the zero concentration calibrator (S0) and the mean of the 3 tests of the adjacent concentration calibrator (S1), a linear equation was obtained by performing a two-point linear regression fit, and the RLU value corresponding to (M+2SD) was substituted into the above equation to calculate the corresponding concentration value, which is the blank limit, which is 0.0055μg / L, as shown in Table 2.

[0119] Table 2: Blank limit luminescence value (RLU) results

[0120]

[0121]

[0122] C. Linear

[0123] The high-value samples close to the upper limit of the measurement range were diluted to 6 concentrations in a certain ratio using the buffer of the calibration product, and the low-value concentration samples were close to the lower limit of the linear range. The samples of each concentration were measured 3 times, and the average value was calculated. The average value of the result and the dilution ratio or theoretical concentration were linearly fitted using the least squares method, and the linear correlation coefficient r was calculated to be 0.9997, as shown in Table 3.

[0124] Table 3: Linearity sample determination results

[0125]

[0126] D. Accuracy

[0127] The kit in Example 1 was tested for accuracy, and the calibration sample was tested three times. The relative deviation of each measurement value was calculated using the following formula. The recovery rate of each point of the calibration sample was within the range of ±10.0%. The measurement results are shown in Table 4.

[0128] The calculation formula is:

[0129]

[0130] Where:

[0131] B i - relative deviation;

[0132] M i ——The i-th measured value;

[0133] T - indicated value.

[0134] Table 4: Accuracy sample test results

[0135]

[0136]

[0137] E. Intra-batch precision

[0138] Take one box of the BAP kit in Example 1, and use the quality control products with concentrations of 10.00 μg / L and 60.00 μg / L to perform the test, repeat 10 times, and calculate the mean value (M), standard deviation (SD) and coefficient of variation (CV). Through the test, it can be seen that the coefficient of variation (CV) of the intra-batch precision of the kit is 3.51% and 4.98%. The intra-batch precision is within the range of ±8.0%, and the test results are shown in Table 5.

[0139] Table 5: Intra-batch precision determination results

[0140]

[0141]

[0142] F. Batch-to-batch precision

[0143] Take one box of each of the three different batches of BAP kits in Example 1, measure the quality control products respectively, repeat 10 times, calculate the mean value (M), standard deviation (SD) and inter-batch coefficient of variation (CV) of the 30 measurement results, and it can be seen from the measurement that the inter-batch precision coefficient of variation (CV) of the kit is 2.86% and 4.42%, respectively. The three batches of kits are used to detect quality control products 1 and quality control products 2, and the inter-batch coefficients of variation are all within the range of ±10%. The measurement results are shown in Tables 6 and 7.

[0144] Table 6: Results of inter-batch precision quality control product 1

[0145]

[0146] Table 7: Results of inter-batch precision quality control product 2

[0147]

[0148]

[0149] G. Anti-interference

[0150] Take 1 box of the BAP kit in Example 1 and perform an anti-interference test. Bilirubin, hemoglobin, triglycerides, and biotin are added to 1 median sample and 1 high value sample, respectively. Each sample is repeated twice. It can be seen from the measurement that the deviations of the measured values ​​of samples with different concentrations of interfering substances added and samples without interfering substances are all within the range of ±10%, and there is no interference. The measurement results are shown in Tables 8 and 9; for samples with a liver ALP content of 100U / L, the result is ≤4.3μg / L, and the measurement results are shown in Table 10.

[0151] Table 8: Interference determination results of sample 1

[0152]

[0153]

[0154] Table 9: Interference determination results of sample 2

[0155]

[0156]

[0157] Table 10: Interference results of liver ALP samples

[0158]

[0159] H. Stability

[0160] a. Acceleration stability

[0161] Three test kits and calibrators from the same batch were placed in a 37°C constant temperature incubator and taken out for testing on the 3rd, 6th and 9th days respectively. The test results were compared with the test kits at 2-8°C. The results showed that the 9-day decrease in the accelerated stability of the reagents and calibrators at 37°C was within 10%, indicating good stability. The test results are shown in Tables 11 and 12.

[0162] Table 11: Results of accelerated stability test of the kit

[0163]

[0164] Table 12: Results of accelerated stability test of calibrators

[0165]

[0166] b. Long-term stability

[0167] The long-term stability of the BAP kit in Example 1 was observed, and the long-term stability period was 13 months. The kit was stored at 2-8°C as required, and the calibrator was tested at 1, 3, 6, 9, 12, and 13 months, respectively, and a -20°C calibrator was added as a control. It was found through the measurement that the kit can be stably stored at 2-8°C for 13 months. The measurement results are shown in Table 13.

[0168] Table 13: Long-term stability test results

[0169]

[0170] Example 4

[0171] The BAP test kit prepared in Example 1 of the present invention and the bone alkaline phosphatase test kit imported from Beckman Coulter were used to test 200 clinical sera collected from the hospital laboratory. The test results are shown in Table 14. The measured values ​​of the Beckman Coulter test kit are used as the horizontal axis, and the measured values ​​of the test kit of the present invention are used as the vertical axis. The results of the two tests are compared and analyzed, as shown in the attached figure. Figure 2 As shown; the correlation equation is: y = 1.0116x-0.0981, the correlation coefficient R 2 =0.9883. This shows that the kit of the present invention has a good correlation with the imported kit.

[0172] Table 14: Sample comparison test results

[0173]

[0174]

[0175]

[0176]

[0177]

[0178] In summary, the BAP kit provided by the present invention has significant innovation and practicality, and its reaction principle is to use bone alkaline phosphatase to directly catalyze the substrate to emit light, eliminating the process of antibody labeling in general chemiluminescent reagents, and is simple to operate. By optimizing the reagent formula and combination method, this kit achieves a high-sensitivity, high-specificity detection effect, and the stability of the calibrator is better than that of imported reagents; at the same time, the sample requirement is small, the reaction time is short, and the detection efficiency is improved. In addition, this kit also has a wide range of applications, meets the current market demand for efficient and convenient detection kits, covers the needs of existing clinical tests, and provides strong support for medical diagnosis, scientific research and other fields, and also provides new ideas and methods for the localization of chemiluminescent reagents.

[0179] Finally, it should be emphasized that the kit described in the present invention is only one of the specific embodiments. For those skilled in the art, various improvements and changes can be made according to actual needs without departing from the principles of the present invention. Therefore, the protection scope of the present invention is not limited to the specific contents of the above embodiments, but should be based on the scope defined in the claims. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A chemiluminescent kit for determining bone alkaline phosphatase, It is characterized in that Including reagent R 1 , Reagent R 2 , Reagent R 3 ; The reagent R 1 It is a goat anti-mouse polyclonal antibody coated on streptavidin magnetic beads and labeled with biotin; The reagent R 2 It is a mouse anti-human BAP specific monoclonal antibody; The reagent R 3 Assay buffer supplemented with goat serum.

2. A chemiluminescent kit for determining bone alkaline phosphatase according to claim 1, It is characterized in that The reagent R 1 The working concentration of goat anti-mouse polyclonal antibody is 1-4 μg / mL, and the working concentration of magnetic beads is 0.1-0.4 mg / mL.

3. A chemiluminescent kit for determining bone alkaline phosphatase according to claim 1, It is characterized in that The reagent R 2 The working concentration of mouse anti-human BAP specific monoclonal antibody is 0.01-0.1 μg / mL.

4. A chemiluminescent kit for determining bone alkaline phosphatase according to claim 1, It is characterized in that The reagent R 3 The concentration of goat serum is 10mL / L.

5. A chemiluminescent kit for determining bone alkaline phosphatase according to claim 1, It is characterized in that The kit also includes calibrators and quality control products; The calibrator comprises BAP antigen solutions with concentrations of 0 μg / L, 4.0 μg / L, 10 μg / L, 30 μg / L, 60 μg / L and 120 μg / L; The quality control product comprises BAP antigen solution with concentrations of 10 μg / mL and 60 μg / mL.

6. A chemiluminescent kit for determining bone alkaline phosphatase according to claim 1, It is characterized in that The reagent R 1 The buffer includes the following components: Tris, NaCl, trehalose, BSA, Proclin300, Tween 20 and 4-aminoantipyrine; The reagent R 2 The buffer includes the following components: Tris, NaCl, trehalose, BSA, Proclin300, Tween 20, 4-aminoantipyrine, fruit green pigment and Triton 100; The reagent R 3 The following components are also included: Tris, NaCl and Proclin300.

7. A method for preparing the chemiluminescent kit for determining bone alkaline phosphatase according to claim 1, It is characterized in that The reagent R 1 The preparation process includes the following steps: (1) Dilute goat anti-mouse polyclonal antibody with PBS and dialyze against PBS; (2) Biotin-labeled antibody: Take biotin ester in a centrifuge tube, add dimethyl sulfoxide to dissolve, and prepare biotin ester solution; add the antibody to the biotin ester solution for reaction, and then add tris(hydroxymethylaminomethane) buffer to terminate the reaction; (3) Dialysis in PBS; (4) recovering the biotin-labeled antibody; (5) Streptavidin magnetic bead coating: Take the streptavidin-labeled magnetic beads and use reagent R 1 , resuspend the magnetic beads and wash; after washing, the streptavidin magnetic beads are suspended in reagent R 1 in a buffer solution; (6) Add the biotin-labeled antibody in step (4) to the streptavidin magnetic beads in step (5), mix and react to obtain reagent R 1 .

8. The method for preparing the chemiluminescent kit for determining bone alkaline phosphatase according to claim 6, It is characterized in that The reagent R 2 The preparation process includes the following steps: (1) Antibody activation: Mouse anti-human BAP-specific monoclonal antibody was diluted with TSE and then dialyzed against TSE; (2) Recovering antibodies; (3) Use reagent R 2 Prepare the antibody with buffer to obtain reagent R 2 .

9. The method for preparing the chemiluminescent kit for determining bone alkaline phosphatase according to claim 6, It is characterized in that Reagent R 3 The preparation process includes the following steps: taking reagent R 3 Buffer solution was added with goat serum at working concentration.

10. Use of the kit according to any one of claims 1 to 6, It is characterized in that Used to detect bone alkaline phosphatase.

Citation Information

Cited By

  • Detection kit for detecting anti-phospholipase A2 receptor antibody IgG as well as preparation method and application thereof

    CN120102871A